BioSight
Companies
IDEAYA Biosciences, Inc. logo

IDYA

NASDAQSOUTH SAN FRANCISCO, CA
IDEAYA Biosciences, Inc.

IDEAYA Biosciences develops small-molecule drug candidates targeting cancer and other diseases through various mechanisms including PKC inhibition, MAT2A inhibition, DLL3 targeting, PARG inhibition, and DNA helicase inhibition. Most of its pipeline candidates are in early-stage development, with darovasertib being the most advanced in Phase 2/3 clinical trials, while several others are in Phase 1 or Phase 1/2 trials.

Price history not yet available for IDYA.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar